Literature DB >> 10768596

Chemotherapy for renal cell carcinoma.

R J Amato1.   

Abstract

Renal cell carcinoma is highly resistant to systemic chemotherapy, and no agent should be considered standard in the treatment of metastatic disease. At this time, it is appropriate for patients with advanced local or metastatic renal cell carcinoma to be offered new therapeutic investigational experimental options, since clearly there are limited therapies presently available. The experience with chemotherapy is reviewed.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10768596

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  52 in total

1.  Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.

Authors:  S J Hotte; G A Bjarnason; D Y C Heng; M A S Jewett; A Kapoor; C Kollmannsberger; J Maroun; L A Mayhew; S North; M N Reaume; J D Ruether; D Soulieres; P M Venner; E W Winquist; L Wood; J H E Yong; F Saad
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

2.  Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review.

Authors:  Christina Canil; Sebastien Hotte; Linda A Mayhew; Tricia S Waldron; Eric Winquist
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

Review 3.  Immunotherapy in metastatic renal cell carcinoma.

Authors:  Karl Rohrmann; Michael Staehler; Nikolas Haseke; Alexander Bachmann; Christian G Stief; Michael Siebels
Journal:  World J Urol       Date:  2005-04-02       Impact factor: 4.226

4.  [Renal cell carcinoma].

Authors:  A Haferkamp; D Rohde; S C Müller; H Rübben; M Hohenfellner
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 5.  [Therapy strategies for advanced renal cell carcinoma].

Authors:  M Staehler; N Haseke; G Schöppler; T Stadler; C Adam; C G Stief
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639

Review 6.  [Systemic therapy of metastatic renal cell carcinoma].

Authors:  M Autenrieth; A Heidenreich; J E Gschwend
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

7.  CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model.

Authors:  Scott S Tykodi; Shoko Satoh; Janise D Deming; Jeffrey Chou; Richard Harrop; Edus H Warren
Journal:  J Immunother       Date:  2012-09       Impact factor: 4.456

8.  Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma.

Authors:  Guan-Xian Liu; Xin Zhang; Su Li; Richard D Koiiche; Jerry H Sindsceii; Haihan Song
Journal:  Tumour Biol       Date:  2013-05-09

Review 9.  Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches.

Authors:  A J Schrader; Z Varga; A Hegele; S Pfoertner; P Olbert; R Hofmann
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-25       Impact factor: 4.553

10.  Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease.

Authors:  Thomas C Wehler; Claudine Graf; Stefan Biesterfeld; Walburgis Brenner; Jörg Schadt; Ines Gockel; Martin R Berger; Joachim W Thüroff; Peter R Galle; Markus Moehler; Carl C Schimanski
Journal:  J Oncol       Date:  2008-12-30       Impact factor: 4.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.